INTRODUCTION
============

Amyotrophic lateral sclerosis (ALS) is characterized by motor neuron degeneration leading to progressive muscle paresis and functional disability, with a mean survival of 3 to 5 years.^([@B1])^ Non-motor symptoms may be seen including depression and anxiety.^([@B1],[@B2])^ The prevalence of depression and anxiety is highly variable among published studies, and may be present in up to 44 and 30% of patients, respectively.^([@B2])^ There is evidence indicating that functional disability and depression are linked, and that depression reduces the quality of life of patients with ALS.^([@B3])^ However, some studies failed to confirm the association between the severity of anxiety and depressive symptoms, and functional disability in ALS.^([@B4],[@B5])^

This study investigated clinical features and anxiety/depressive symptoms in Brazilian patients with ALS. We hypothesized that the presence of anxiety and depression would be related to a more significant functional impairment.

OBJECTIVE
=========

To investigate the frequency of anxiety and depression and their association with clinical features of amyotrophic lateral sclerosis.

METHODS
=======

This is a cross-sectional study of consecutive patients diagnosed with probable or definite sporadic ALS according to Awaji's criteria^([@B6])^ conducted from May 2013 to November 2015. All patients signed the written consent.

The protocol included standardized questions regarding clinical features of ALS, the Hospital Anxiety and Depression Scale (HADS)^([@B7],[@B8])^ and the ALS Functional Rating Scale Revised (ALSFRS-R).^([@B9])^ A total score on HADS for depression above 8 is highly indicative of clinically significant depression (*i.e*. probable depression); the same criteria was applied for anxiety.^([@B8])^

The study was approved by the human research Ethics Committee of both *Universidade Federal de Minas Gerais*, CAAE: 19599813.0.0000.5149 and *Fundação Hospitalar do Estado de Minas Gerais,* protocol number 002B/2014.

Statistical analysis
--------------------

We performed non-parametric tests (Mann-Whitney, χ^2^ and Spearman) using Statistical Package for the Social Sciences (SPSS), version 22.0. A p value \<0.05 was considered statistically significant.

RESULTS
=======

Seventy-six patients were selected for the study. The clinical parameters are summarized at [table 1](#t1){ref-type="table"}. Forty-seven patients (61.8%) were men (men/women ratio: 1.6:1). Considering the initial presentation, 78% of cases were spinal and 22% were bulbar.

Table 1Descriptive analysis of clinical parameters of patients with amyotrophic lateral sclerosisSporadic ALS (n=76)Mean (SD±)MedianMinimunMaximunAge at the onset of symptoms, years55.0 (12.1)552682Age at assessment, years58.3 (11.6)583283Disease duration until assessment, years3.32 (2.8)2014[^2]

Sixty-six patients (86.8%) completed the HADS ([Table 2](#t2){ref-type="table"}). The others did not fulfill the scale due to refusal (n=4) or severe disability (n=6). Probable anxiety was confirmed in 23 (34.8%) patients; probable depression was found in 24 (36.4%) patients. Of 66 patients, 65% were men, 50 (75%) had spinal and 16 (24%) had bulbar initial presentation. Fifteen (23%) had anxiety and depression, 9 (14%) had only depression, 8 (12%) had only anxiety, while 34 (51%) had none of these symptoms. Thirty patients were current using antidepressants to treat depressive state and/or pain, insomnia or excessive salivation. Eleven of 24 patients with depression (45.8%) were using effective doses of antidepressants.

Table 2Descriptive analysis of clinical parameters of patients with amyotrophic lateral sclerosis who completed Hospital Anxiety and Depression ScaleSporadic ALS (n=66)Mean (SD±)MedianMinimunMaximunAge at the onset, years54.3 (12.1)552682Age at assessment, years57.6 (11.5)57,53283Score on ALSFRS-R26.9 (10.1)27046Score on HADS-anxiety7.2 (4.4)6017Score on HADS-depression6.7 (4.5)7018[^3]

When we compared subgroups of patients according to the presence or not of probable depression, there was a statistical difference regarding the score on HADS for anxiety ([Table 3](#t3){ref-type="table"}). No significant difference was found regarding sex and initial form.

Table 3Comparative analysis of subgroups of patients, according to presence or the absence of significant depressive symptoms (Hospital Anxiety and Depression Scale for depression ≥9) Depression  YesNop valuenmean (r)nmean (r)Years of study246.4 (3-19)427.3 (0-20)0.66Age at the onset of disease, years2458.1 (41-76)4252.1 (26-82)0.06Anxiety2410.8 (4-17)425.2 (0-15)0.00\*Score on ALSFRS-R2425.8 (0-46)4227.6 (4-46)0.44Disease duration, years243.0 (0-11)423.4 (0-14)0.60[^4][^5]

We did further analysis comparing subgroups of patients categorized according to the presence or not of anxiety and or depression, and no significant difference regarding ALSFRS-R scores, sex, age at onset, disease duration and initial form emerged.

There was no correlation between HADS scores for anxiety or depression and ALSFRS-R scores. A positive correlation between anxiety and depressive symptoms was found (r=0.67; p\<0.001).

DISCUSSION
==========

To the best of our knowledge, this is the first study assessing psychiatric symptoms in ALS patients from South America. The frequency of depression (zero to 44%) and anxiety (zero to 30%) in ALS varies significantly across the studies.^([@B2],[@B3],[@B4])^ Our rates (around 35%) are within the range reported in the literature.

The assessment of psychiatric symptoms in ALS may be hampered by several factors, including assessment tools^([@B10])^ and severity of the disease,^([@B3],[@B11])^ partly explaining the discrepancy among studies. Moreover, the use of antidepressants, that is frequent in ALS for different reasons,^([@B2]-[@B4],[@B12])^ may have influenced the frequency and/or severity of depressive and anxiety symptoms.

Interestingly, despite the use of antidepressants, psychiatric symptoms are prominent, indicating persistence of symptoms even with treatment.^([@B2],[@B3],[@B12])^ It remains to be defined whether these patients respond differently to antidepressants and which factors are associated to clinical response.

Contrary to our hypothesis, we did not find significant association between symptoms of anxiety/depression and functional disability. The absence of association between depression and disease duration or functional score in ALS were reported in some studies,^([@B4],[@B5])^ but other authors did find this association.^([@B3])^ Methodological issues, including differences in the selection criteria of patients and in the choice of the functional and psychiatric scales may account for these distinct findings. The controversial findings in literature hamper a precise conclusion about this subject. Further studies could help to clarify this data.

Based on the absence of significant difference in clinical features between subgroups, it is possible that these psychiatric symptoms may be due to other reasons not related to motor and functional impairment. It also remains to be elucidated why anxiety and depression symptoms were highly correlated in ALS. Limitations of the study include sample size, bias of the use of antidepressants and intrinsic limitations of the HADS.

CONCLUSION
==========

The frequency of anxiety and depression in amyotrophic lateral sclerosis was elevated, and was not associated with disease duration, sex, presentation form and functional score. There was a high correlation between anxiety and depression symptoms in amyotrophic lateral sclerosis.

[^1]: Conflict of interest: none.

[^2]: ALS: amyotrophic lateral sclerosis; SD: standard deviation.

[^3]: ALS: amyotrophic lateral sclerosis; ALSFRS-R: amyotrophic lateral sclerosis functional rating scale revised; HADS: hospital anxiety and depression scale; SD: standard deviation.
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